BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 31087223)

  • 1. Zelnorm, an agonist of 5-Hydroxytryptamine 4-receptor, acts as a potential antitumor drug by targeting JAK/STAT3 signaling.
    Zhang L; Song Q; Zhang X; Li L; Xu X; Xu X; Li X; Wang Z; Lin Y; Li X; Li M; Su F; Wang X; Qiu P; Guan H; Tang Y; Xu W; Yang J; Zhao C
    Invest New Drugs; 2020 Apr; 38(2):311-320. PubMed ID: 31087223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.
    Bharadwaj U; Kasembeli MM; Robinson P; Tweardy DJ
    Pharmacol Rev; 2020 Apr; 72(2):486-526. PubMed ID: 32198236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 6-Bromoindirubin-3'-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells.
    Liu L; Nam S; Tian Y; Yang F; Wu J; Wang Y; Scuto A; Polychronopoulos P; Magiatis P; Skaltsounis L; Jove R
    Cancer Res; 2011 Jun; 71(11):3972-9. PubMed ID: 21610112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SP2509, an inhibitor of LSD1, exerts potential antitumor effects by targeting the JAK/STAT3 signaling.
    Zhen H; Zhang X; Zhang L; Zhou M; Lu L; Wu L; He N; Wang J; Li R; Guo Y
    Acta Biochim Biophys Sin (Shanghai); 2021 Jul; 53(8):1098-1105. PubMed ID: 34169322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively-activated Stat3 signaling associated with apoptosis of human pancreatic cancer cells.
    Nam S; Wen W; Schroeder A; Herrmann A; Yu H; Cheng X; Merz KH; Eisenbrand G; Li H; Yuan YC; Jove R
    Mol Oncol; 2013 Jun; 7(3):369-78. PubMed ID: 23206899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and evaluation of Atopaxar hydrobromide, a novel JAK1 and JAK2 inhibitor, selectively induces apoptosis of cancer cells with constitutively activated STAT3.
    Sun J; Du Y; Zhang X; Wang Z; Lin Y; Song Q; Wang X; Guo J; Li S; Nan J; Yang J
    Invest New Drugs; 2020 Aug; 38(4):1003-1011. PubMed ID: 31612426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells.
    Chen X; Du Y; Nan J; Zhang X; Qin X; Wang Y; Hou J; Wang Q; Yang J
    PLoS One; 2013; 8(5):e63697. PubMed ID: 23704931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
    Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH
    Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells.
    Wang Y; Ma X; Yan S; Shen S; Zhu H; Gu Y; Wang H; Qin G; Yu Q
    Cancer Res; 2009 Sep; 69(18):7302-10. PubMed ID: 19706767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications.
    Liu W; Stachura P; Xu HC; Umesh Ganesh N; Cox F; Wang R; Lang KS; Gopalakrishnan J; Häussinger D; Homey B; Lang PA; Pandyra AA
    J Exp Clin Cancer Res; 2020 Feb; 39(1):38. PubMed ID: 32085796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.
    Murone M; Vaslin Chessex A; Attinger A; Ramachandra R; Shetty SJ; Daginakatte G; Sengupta S; Marappan S; Dhodheri S; Rigotti S; Bachhav Y; Brienza S; Traxler P; Lang M; Aguet M; Zoete V; Michielin O; Nicholas C; Johnson FM; Ramachandra M; McAllister A
    Mol Cancer Ther; 2016 Oct; 15(10):2334-2343. PubMed ID: 27439479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
    Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
    Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells.
    Duan Z; Bradner J; Greenberg E; Mazitschek R; Foster R; Mahoney J; Seiden MV
    Mol Pharmacol; 2007 Nov; 72(5):1137-45. PubMed ID: 17675586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of the JAK-STAT3 pathway is associated with the growth of colorectal carcinoma cells.
    Wei X; Wang G; Li W; Hu X; Huang Q; Xu K; Lou W; Wu J; Liang C; Lou Q; Qian C; Liu L
    Oncol Rep; 2014 Jan; 31(1):335-41. PubMed ID: 24253664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.
    Burger R; Le Gouill S; Tai YT; Shringarpure R; Tassone P; Neri P; Podar K; Catley L; Hideshima T; Chauhan D; Caulder E; Neilan CL; Vaddi K; Li J; Gramatzki M; Fridman JS; Anderson KC
    Mol Cancer Ther; 2009 Jan; 8(1):26-35. PubMed ID: 19139110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.
    Blaskovich MA; Sun J; Cantor A; Turkson J; Jove R; Sebti SM
    Cancer Res; 2003 Mar; 63(6):1270-9. PubMed ID: 12649187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects.
    Johnson FM; Saigal B; Tran H; Donato NJ
    Clin Cancer Res; 2007 Jul; 13(14):4233-44. PubMed ID: 17634553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physapubescin B enhances the sensitivity of gastric cancer cells to trametinib by inhibiting the STAT3 signaling pathway.
    Dai C; Shen L; Jin W; Lv B; Liu P; Wang X; Yin Y; Fu Y; Liang L; Ma Z; Zhang X; Wang Y; Xu D; Chen Z
    Toxicol Appl Pharmacol; 2020 Dec; 408():115273. PubMed ID: 33035574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-angiogenic activity of thienopyridine derivative LCB03-0110 by targeting VEGFR-2 and JAK/STAT3 Signalling.
    Kim BH; Lee Y; Yoo H; Cui M; Lee S; Kim SY; Cho JU; Lee H; Yang BS; Kwon YG; Choi S; Kim TY
    Exp Dermatol; 2015 Jul; 24(7):503-9. PubMed ID: 25808463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting JAK kinase in solid tumors: emerging opportunities and challenges.
    Buchert M; Burns CJ; Ernst M
    Oncogene; 2016 Feb; 35(8):939-51. PubMed ID: 25982279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.